Reduced brain somatostatin in mood disorders: A common pathophysiological substrate and drug target?

Frontiers in Pharmacology

Volumn 4 SEP, Issue , 2013, Pages

  Lin, Li Chun ^a   Sibille, Etienne ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; GABA inhibition; Mood disorders; SOM; Somatostatin; Somatostatin expressing interneurons; SRIF; SST

Indexed keywords

4 AMINOBUTYRIC ACID; ACQ 090; ANGIOPEPTIN; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CARBAMAZEPINE; CITALOPRAM; CORTISTATIN; DOPAMINE 2 RECEPTOR; IMIPRAMINE; MAPROTILINE; MIANSERIN; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPEPTIDE Y; OCTREOTIDE; PASIREOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; SRA 880; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZOTEPINE;

ACROMEGALY; AGING; ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; AUTOPSY; BIPOLAR DISORDER; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DENDRITE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EPILEPSY; GENETIC POLYMORPHISM; HEADACHE; HUMAN; INFLAMMATION; INTERNEURON; MAJOR DEPRESSION; MOOD DISORDER; NERVE CELL NETWORK; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PAIN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TEMPORAL CORTEX; TRANQUILIZING ACTIVITY;

EID: 84885350213     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00110     Document Type: Review

References (171)

1. Aarsland, D., Larsen, J. P., Lim, N. G., Janvin, C., Karlsen, K., Tandberg, E., et al. (1999). Range of neuropsychiatric disturbances in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67, 492-496. doi:10.1136/jnnp.67.4.492.
2. Agren, H., and Lundqvist, G. (1984). Low levels of somatostatin in human CSF mark depressive episodes. Psychoneuroendocrinology 9, 233-248. doi:10.1016/0306-4530(84)90003-9.
3. Barrett, D. M., Black, S. M., Todor, H., Schmidt-Ullrich, R. K., Dawson, K. S., and Mikkelsen, R. B. (2005). Inhibition of protein-tyrosine phosphatases by mild oxidative stresses is dependent on S-nitrosylation. J. Biol. Chem. 280, 14453-14461. doi:10.1074/jbc. M411523200.
4. Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach. P., et al. (1982). SMS 201-995:a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31, 1133-1140. doi:10.1016/0024-3205(82)90087-X.
5. Baxter, L. R. Jr., Phelps, M. E., Mazziotta, J. C., Schwartz, J. M., Gerner, R. H., Selin, C. E. et al. (1985). Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch. Gen. Psychiatry 42, 441-447. doi:10.1001/archpsyc.1985.01790280019002.
6. Baxter, L. R. Jr., Schwartz, J. M., Phelps, M. E., Mazziotta, J. C., Guze, B. H., Selin, C. E. et al. (1989). Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry 46, 243-250. doi:10.1001/archpsyc.1989.01810030049007.
7. Beal, M. F., Mazurek, M. F., and Martin, J. B. (1986). Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Res. 397, 386-388. doi:10.1016/0006-8993(86)90644-X.
8. Beierlein, M., Gibson, J. R., and Connors, B. W. (2003). Two dynamically distinct inhibitory networks in layer 4 of the neocortex. J. Neurophysiol. 90, 2987-3000. doi:10.1152/jn.00283.2003.
9. Bevan, J. S. (2005). The antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90, 1856-1863. doi:10.1210/jc.2004-1093.
10. Bissette, G., Widerlov, E., Walleus, H., Karlsson, I., Eklund, K., Forsman, A., et al. (1986). Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders. Arch. Gen. Psychiatry 43, 1148-1151. doi:10.1001/archpsyc.1986.01800120034008.
11. Bruunsgaard, H., and Pedersen, B. K. (2003). Age-related inflammatory cytokines and disease. Immunol. Allergy Clin. North Am. 23, 15-39. doi:10.1016/S0889-8561(02)00056-5.
12. Bungener, C., Jouvent, R., and Derouesne, C. (1996). Affective disturbances in Alzheimer's disease. J. Am. Geriatr. Soc. 44, 1066-1071.
13. Burnett, B. B., Gardner, A., and Boles, R. G. (2005). Mitochondrial inheritance in depression, dysmotility and migraine? J. Affect Disord. 88, 109-116. doi:10.1016/j.jad.2005.05.009.
14. Candy, J. M., Gascoigne, A. D., Biggins, J. A., Smith, A. I., Perry, R. H., Perry, E. K., et al. (1985). Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease. J. Neurol. Sci. 71, 315-323. doi:10.1016/0022-510X(85)90070-X.
15. Castera, L., Constant, A., Henry, C., Champbenoit, P., Bernard, P. H., De Ledinghen, V., et al. (2006). Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment. Pharmacol. Ther. 24, 1223-1230. doi:10.1111/j.1365-2036.2006.03107.x.
16. Celik, C., Erdem, M., Cayci, T., Ozdemir, B., Ozgur Akgul, E., Kurt, Y. G., et al. (2010). The association between serum levels of neopterin and number of depressive episodes of major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 372-375. doi:10.1016/j.pnpbp.2010.01.002.
17. Chiu, C. Q., Lur, G., Morse, T. M., Carnevale, N. T., Ellis-Davies, G. C., and Higley, M. J. (2013). Compartmentalization of GABAergic inhibition by dendritic spines. Science 340, 759-762. doi:10.1126/science.1234274.
18. Chung, K., Wallace, J., Kim, S. Y., Kalyanasundaram, S., Andalman, A. S., Davidson, T. J., et al. (2013). Structural and molecular interrogation of intact biological systems. Nature 497, 332-337. doi:10.1038/nature12107.
19. Cruikshank, S. J., Urabe, H., Nurmikko, A. V., and Connors, B. W. (2010). Pathway-specific feedforward circuits between thalamus and neocortex revealed by selective optical stimulation of axons. Neuron 65, 230-245. doi:10.1016/j.neuron.2009.12.025.
20. Csaba, Z., and Dournaud, P. (2001). Cellular biology of somatostatin receptors. Neuropeptides 35, 1-23. doi:10.1054/npep.2001.0848.
21. Davies, P., Katzman, R., and Terry, R. D. (1980). Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature 288, 279-280. doi:10.1038/288279a0.
22. Davies, P., and Terry, R. D. (1981). Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. Neurobiol. Aging 2, 9-14. doi:10.1016/0197-4580(81)90053-1.
23. DeFelipe, J., Lopez-Cruz, P. L., Benavides-Piccione, R., Bielza, C., Larranaga, P., Anderson, S., et al. (2013). New insights into the classification and nomenclature of cortical GABAergic interneurons. Nat. Rev. Neurosci. 14, 202-216. doi:10.1038/nrn3444.
24. de Lecea, L. (2008). Cortistatin-functions in the central nervous system. Mol. Cell. Endocrinol. 286, 88-95. doi:10.1016/j.mce.2007.12.014.
25. de Lecea, L., Criado, J. R., Prospero-Garcia, O., Gautvik, K. M., Schweitzer, P., Danielson, P. E., et al. (1996). A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381, 242-245. doi:10.1038/381242a0.
26. de Lecea, L., del Rio, J. A., Criado, J. R., Alcantara, S., Morales, M., Danielson, P. E., et al. (1997). Cortistatin is expressed in a distinct subset of cortical interneurons. J. Neurosci. 17, 5868-5880.
27. Di Cristo, G., Wu, C., Chattopadhyaya, B., Ango, F., Knott, G., Welker, E., et al. (2004). Subcellular domain-restricted GABAergic innervation in primary visual cortex in the absence of sensory and thalamic inputs. Nat. Neurosci. 7, 1184-1186. doi:10.1038/nn1334.
28. Di Filippo, M., Sarchielli, P., Picconi, B., and Calabresi, P. (2008). Neuroinflammation and synaptic plasticity:theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol. Sci. 29, 402-412. doi:10.1016/j.tips.2008.06.005.
29. Douillard-Guilloux, G., Guilloux, J. P., Lewis, D. A., and Sibille, E. (2013). Anticipated brain molecular aging in major depression. Am. J. Geriatr. Psychiatry 21, 450-460. doi:10.1016/j.jagp.2013.01.040.
30. Dournaud, P., Cervera-Pierot, P., Hirsch, E., Javoy-Agid, F., Kordon, C., Agid, Y., et al. (1994). Somatostatin messenger RNA-containing neurons in Alzheimer's disease:an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neuroscience 61, 755-764. doi:10.1016/0306-4522(94)90399-9.
31. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., et al. (2010). A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446-457. doi:10.1016/j.biopsych.2009.09.033.
32. Dun, N. J., Dun, S. L., Wong, R. K., and Forstermann, U. (1994). Colocalization of nitric oxide synthase and somatostatin immunoreactivity in rat dentate hilar neurons. Proc. Natl. Acad. Sci. U.S.A. 91, 2955-2959. doi:10.1073/pnas.91.8.2955.
33. Dupont, E., Christensen, S. E., Hansen, A. P., de Fine Olivarius, B., and Orskov, H. (1982). Low cerebrospinal fluid somatostatin in Parkinson disease:an irreversible abnormality. Neurology 32, 312-314. doi:10.1212/WNL.32.3.312.
34. Engin, E., Stellbrink, J., Treit, D., and Dickson, C. T. (2008). Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin:behavioral and neurophysiological evidence. Neuroscience 157, 666-676. doi:10.1016/j.neuroscience.2008.09.037.
35. Engin, E., and Treit, D. (2009). Anxiolytic and antidepressant actions of somatostatin:the role of sst2 and sst3 receptors. Psychopharmacology (Berl.) 206, 281-289. doi:10.1007/s00213-009-1605-5.
36. Epelbaum, J. (1986). Somatostatin in the central nervous system:physiology and pathological modifications. Prog. Neurobiol. 27, 63-100. doi:10.1016/0301-0082(86)90012-2.
37. Epelbaum, J., Javoy-Agid, F., Enjalbert, A., Krantic, S., Kordon, C., and Agid, Y. (1988). Somatostatin concentrations and binding sites in human frontal cortex are differentially affected in Parkinson's disease associated dementia and in progressive supranuclear palsy. J. Neurol. Sci. 87, 167-174. doi:10.1016/0022-510X(88)90242-0.
38. Erickson, K. I., Prakash, R. S., Voss, M. W., Chaddock, L., Heo, S., McLaren, M., et al. (2010). Brain-derived neurotrophic factor is associated with age-related decline in hippocampal volume. J. Neurosci. 30, 5368-5375. doi:10.1523/JNEUROSCI.6251-09.2010.
39. Erraji-Benchekroun, L., Underwood, M. D., Arango, V., Galfalvy, H., Pavlidis, P., Smyrniotopoulos, P., et al. (2005). Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol. Psychiatry 57, 549-558. doi:10.1016/j.biopsych.2004.10.034.
40. Festinger, D. S., Marlowe, D. B., Dugosh, K. L., Croft, J. R., and Arabia, P. L. (2008). Higher magnitude cash payments improve research follow-up rates without increasing drug use or perceived coercion. Drug Alcohol Depend. 96, 128-135. doi:10.1016/j.drugalcdep.2008.02.007.
41. Figueredo-Cardenas, G., Morello, M., Sancesario, G., Bernardi, G., and Reiner, A. (1996). Colocalization of somatostatin, neuropeptide Y, neuronal nitric oxide synthase and NADPH-diaphorase in striatal interneurons in rats. Brain Res. 735, 317-324. doi:10.1016/0006-8993(96)00801-3.
42. Fishell, G., and Rudy, B. (2011). Mechanisms of inhibition within the telencephalon:"where the wild things are". Annu. Rev. Neurosci. 34, 535-567. doi:10.1146/annurev-neuro-061010-113717.
43. Fitz-Patrick, D., and Patel, Y. C. (1981). Evidence for somatostatin precursors in human stomach, placenta, and amniotic fluid. J. Clin. Endocrinol. Metab. 53, 372-376. doi:10.1210/jcem-53-2-372.
44. Gardner, A., Johansson, A., Wibom, R., Nennesmo, I., von Dobeln, U., Hagenfeldt, L., et al. (2003). Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J. Affect. Disord. 76, 55-68. doi:10.1016/S0165-0327(02)00067-8.
45. Gavilan, M. P., Revilla, E., Pintado, C., Castano, A., Vizuete, M. L., Moreno-González, I., et al. (2007). Molecular and cellular characterization of the age-related neuroinflammatory processes occurring in normal rat hippocampus:potential relation with the loss of somatostatin GABAergic neurons. J. Neurochem. 103, 984-996. doi:10.1111/j.1471-4159.2007.04787.x.
46. Geller, B., Tillman, R., Bolhofner, K., Zimerman, B., Strauss, N. A., and Kaufmann, P. (2006). Controlled, blindly rated, direct-interview family study of a prepubertal and early-adolescent bipolar I disorder phenotype:morbid risk, age at onset, and comorbidity. Arch. Gen. Psychiatry 63, 1130-1138. doi:10.1001/archpsyc.63.10.1130.
47. Gentet, L. J., Kremer, Y., Taniguchi, H., Huang, Z. J., Staiger, J. F., and Petersen, C. C. (2012). Unique functional properties of somatostatin-expressing GABAergic neurons in mouse barrel cortex. Nat. Neurosci. 15, 607-612. doi:10.1038/nn.3051.
48. Glorioso, C., Oh, S., Douillard, G. G., and Sibille, E. (2011). Brain molecular aging, promotion of neurological disease and modulation by sirtuin 5 longevity gene polymorphism. Neurobiol. Dis. 41, 279-290. doi:10.1016/j.nbd.2010.09.016.
49. Glorioso, C., Sabatini, M., Unger, T., Hashimoto, T., Monteggia, L. M., Lewis, D. A., et al. (2006). Specificity and timing of neocortical transcriptome changes in response to BDNF gene ablation during embryogenesis or adulthood. Mol. Psychiatry 11, 633-648. doi:10.1038/sj.mp.4001835.
50. Gonchar, Y., and Burkhalter, A. (1997). Three distinct families of GABAergic neurons in rat visual cortex. Cereb. Cortex 7, 347-358. doi:10.1093/cercor/7.4.347.
51. Gonchar, Y., Wang, Q., and Burkhalter, A. (2007). Multiple distinct subtypes of GABAergic neurons in mouse visual cortex identified by triple immunostaining. Front. Neuroanat. 1:3. doi:10.3389/neuro.05.003.2007.
52. Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., et al. (2008). Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry 13, 717-728. doi:10.1038/sj.mp.4002055.
53. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. (2013). TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127. doi:10.1056/NEJMoa1211851.
54. Guilloux, J. P., Douillard-Guilloux, G., Kota, R., Wang, X., Gardier, A. M., Martinowich, K., et al. (2012). Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol. Psychiatry 17, 1130-1142. doi:10.1038/mp.2011.113.
55. Guillozet-Bongaarts, A. L., Hyde, T. M., Dalley, R. A., Hawrylycz, M. J., Henry, A., Hof, P. R., et al. (2013). Altered gene expression in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry. doi:10.1038/mp.2013.30 [Epub ahead of print].
56. Haffer, K. N. (2012). Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice. J. Anim. Sci. Biotechnol. 3, 21. doi:10.1186/2049-1891-3-21.
57. Helyes, Z., Szabo, A., Nemeth, J., Jakab, B., Pinter, E., Banvolgyi, A., et al. (2004). Antiinflammatory and analgesic effects of somatostatin released from capsaicin-sensitive sensory nerve terminals in a Freund's adjuvant-induced chronic arthritis model in the rat. Arthritis Rheum. 50, 1677-1685. doi:10.1002/art.20184.
58. Hodes, G. E., Brookshire, B. R., Hill-Smith, T. E., Teegarden, S. L., Berton, O., and Lucki, I. (2012). Strain differences in the effects of chronic corticosterone exposure in the hippocampus. Neuroscience 222, 269-280. doi:10.1016/j.neuroscience.2012.06.017.
59. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J. C., Carrasquillo, M. M., et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435. doi:10.1038/ng.803.
60. Holsboer, F. (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477-501. doi:10.1016/S0893-133X(00)00159-7.
61. Howren, M. B., Lamkin, D. M., and Suls, J. (2009). Associations of depression with C-reactive protein, IL-1, and IL-6:a meta-analysis. Psychosom. Med. 71, 171-186. doi:10.1097/PSY.0b013e3181907c1b.
62. Hoyer, D., Nunn, C., Hannon, J., Schoeffter, P., Feuerbach, D., Schuepbach, E., et al. (2004). SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci. Lett. 361, 132-135. doi:10.1016/j.neulet.2004.02.017.
63. Jaglin, X. H., Hjerling-Leffler, J., Fishell, G., and Batista-Brito, R. (2012). The origin of neocortical nitric oxide synthase-expressing inhibitory neurons. Front. Neural Circuits 6:44. doi:10.3389/fncir.2012.00044.
64. Kaestner, F., Hettich, M., Peters, M., Sibrowski, W., Hetzel, G., Ponath, G., et al. (2005). Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 87, 305-311. doi:10.1016/j.jad.2005.03.012.
65. Kakigi, T., Maeda, K., Kaneda, H., and Chihara, K. (1992). Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain. J. Affect. Disord. 25, 215-220. doi:10.1016/0165-0327(92)90078-K.
66. Kapicioglu, S., Gokce, E., Kapicioglu, Z., and Ovali, E. (1997). Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). Cephalalgia 17, 27-30. doi:10.1046/j.1468-2982.1997.1701027.x.
67. Kawaguchi, Y., and Kubota, Y. (1997). GABAergic cell subtypes and their synaptic connections in rat frontal cortex. Cereb. Cortex 7, 476-486. doi:10.1093/cercor/7.6.476.
68. Ke, M. T., Fujimoto, S., and Imai, T. (2013). SeeDB:a simple and morphology-preserving optical clearing agent for neuronal circuit reconstruction. Nat. Neurosci. 16, 1154-1161. doi:10.1038/nn.3447.
69. Kling, M. A., Rubinow, D. R., Doran, A. R., Roy, A., Davis, C. L., Calabrese, J. R., et al. (1993). Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression:relationship to indices of corticotropin-releasing hormone and cortisol secretion. Neuroendocrinology 57, 79-88. doi:10.1159/000126345.
70. Kluxen, F. W., Bruns, C., and Lubbert, H. (1992). Expression cloning of a rat brain somatostatin receptor cDNA. Proc. Natl. Acad. Sci. U.S.A. 89, 4618-4622. doi:10.1073/pnas.89.10.4618.
71. Koch, B. D., Blalock, J. B., and Schonbrunn, A. (1988). Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. I. An increase in potassium conductance is responsible for both the hyperpolarization and the decrease in intracellular free calcium produced by somatostatin. J. Biol. Chem. 263, 216-225.
72. Koch, B. D., and Schonbrunn, A. (1984). The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes. Endocrinology 114, 1784-1790. doi:10.1210/endo-114-5-1784.
73. Konradi, C., Yang, C. K., Zimmerman, E. I., Lohmann, K. M., Gresch, P., Pantazopoulos, H., et al. (2011a). Hippocampal interneurons are abnormal in schizophrenia. Schizophr. Res. 131, 165-173. doi:10.1016/j.schres.2011.06.007.
74. Konradi, C., Zimmerman, E. I., Yang, C. K., Lohmann, K. M., Gresch, P., Pantazopoulos, H., et al. (2011b). Hippocampal interneurons in bipolar disorder. Arch. Gen. Psychiatry 68, 340-350. doi:10.1001/archgenpsychiatry.2010.175.
75. Koo, J. W., and Duman, R. S. (2008). IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U.S.A. 105, 751-756. doi:10.1073/pnas.0708092105.
76. Kornstein, S. G., Schatzberg, A. F., Thase, M. E., Yonkers, K. A., McCullough, J. P., Keitner, G. I., et al. (2000). Gender differences in chronic major and double depression. J. Affect. Disord. 60, 1-11. doi:10.1016/S0165-0327(99)00158-5.
77. Kurnatowska, I., and Pawlikowski, M. (2000). Effect of somatostatin analog-octreotide on the adjuvant arthritis in rat. Neuro Endocrinol. Lett. 21, 121-126.
78. Lauritsen, M. B., Nyegaard, M., Betancur, C., Colineaux, C., Josiassen, T. L., Kruse, T. A., et al. (2003). Analysis of transmission of novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene in patients with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 121B,100-104. doi:10.1002/ajmg.b.20050.
79. Leach, L. S., Christensen, H., Mackinnon, A. J., Windsor, T. D., and Butterworth, P. (2008). Gender differences in depression and anxiety across the adult lifespan:the role of psychosocial mediators. Soc. Psychiatry Psychiatr. Epidemiol. 43, 983-998. doi:10.1007/s00127-008-0388-z.
80. Lee, S., Hjerling-Leffler, J., Zagha, E., Fishell, G., and Rudy, B. (2010). The largest group of superficial neocortical GABAergic interneurons expresses ionotropic serotonin receptors. J. Neurosci. 30, 16796-16808. doi:10.1523/JNEUROSCI.1869-10.2010.
81. Le Magueresse, C., and Monyer, H. (2013). GABAergic interneurons shape the functional maturation of the cortex. Neuron 77, 388-405. doi:10.1016/j.neuron.2013.01.011.
82. Lin, M. T., and Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795. doi:10.1038/nature05292.
83. Livet, J., Weissman, T. A., Kang, H., Draft, R. W., Lu, J., Bennis, R. A., et al. (2007). Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450, 56-62. doi:10.1038/nature06293.
84. Lotrich, F. E., Rabinovitz, M., Gironda, P., and Pollock, B. G. (2007). Depression following pegylated interferon-alpha:characteristics and vulnerability. J. Psychosom. Res. 63, 131-135. doi:10.1016/j.jpsychores.2007.05.013.
85. Maciag, D., Hughes, J., O'Dwyer, G., Pride, Y., Stockmeier, C. A., Sanacora, G., et al. (2010). Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression:relevance to neuroimaging studies. Biol. Psychiatry 67, 465-470. doi:10.1016/j.biopsych.2009.10.027.
86. Maes, M. (2011). Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 664-675. doi:10.1016/j.pnpbp.2010.06.014.
87. Maes, M., Mihaylova, I., Kubera, M., and Ringel, K. (2012). Activation of cell-mediated immunity in depression:association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 36, 169-175. doi:10.1016/j.pnpbp.2011.09.006.
88. Mancuso, C., Scapagini, G., Curro, D., Giuffrida Stella, A. M., De Marco, C., Butterfield, D. A., et al. (2007). Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 12:1107-1123. doi:10.2741/2130.
89. Markram, H., Toledo-Rodriguez, M., Wang, Y., Gupta, A., Silberberg, G., and Wu, C. (2004). Interneurons of the neocortical inhibitory system. Nat. Rev. Neurosci. 5, 793-807. doi:10.1038/nrn1519.
90. Martel, G., Dutar, P., Epelbaum, J., and Viollet, C. (2012). Somatostatinergic systems:an update on brain functions in normal and pathological aging. Front. Endocrinol. (Lausanne) 3:154. doi:10.3389/fendo.2012.00154.
91. Martinowich, K., Schloesser, R. J., Jimenez, D. V., Weinberger, D. R., and Lu, B. (2011). Activity-dependent brain-derived neurotrophic factor expression regulates cortistatin-interneurons and sleep behavior. Mol. Brain 4, 11. doi:10.1186/1756-6606-4-11.
92. McGuffin, P., Rijsdijk, F., Andrew, M., Sham, P., Katz, R., and Cardno, A. (2003). The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry 60, 497-502. doi:10.1001/archpsyc.60.5.497.
93. Miller, A. H., Maletic, V., and Raison, C. L. (2009). Inflammation and its discontents:the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741. doi:10.1016/j.biopsych.2008.11.029.
94. Molchan, S. E., Hill, J. L., Martinez, R. A., Lawlor, B. A., Mellow, A. M., Rubinow, D. R., et al. (1993). CSF somatostatin in Alzheimer's disease and major depression:relationship to hypothalamic-pituitary-adrenal axis and clinical measures. Psychoneuroendocrinology 18, 509-519. doi:10.1016/0306-4530(93)90044-L.
95. Molchan, S. E., Lawlor, B. A., Hill, J. L., Martinez, R. A., Davis, C. L., Mellow, A. M., et al. (1991). CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biol. Psychiatry 29, 1110-1118. doi:10.1016/0006-3223(91)90253-I.
96. Molitch, M. E. (2008). Lanreotide Autogel in the management of acromegaly. Drugs 68, 724. doi:10.2165/00003495-200868050-00014.
97. Mollenholt, P., Rawal, N., Gordh, T. Jr., and Olsson, Y. (1994). Intrathecal and epidural somatostatin for patients with cancer. Analgesic effects and postmortem neuropathologic investigations of spinal cord and nerve roots. Anesthesiology 81, 534-542. doi:10.1097/00000542-199409000-00004.
98. Moller, L. N., Stidsen, C. E., Hartmann, B., and Holst, J. J. (2003). Somatostatin receptors. Biochim. Biophys. Acta 1616, 1-84. doi:10.1016/S0005-2736(03)00235-9.
99. Montminy, M. R., Sevarino, K. A., Wagner, J. A., Mandel, G., and Goodman, R. H. (1986). Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc. Natl. Acad. Sci. U.S.A. 83, 6682-6686. doi:10.1073/pnas.83.18.6682.
100. Morris, H. M., Hashimoto, T., and Lewis, D. A. (2008). Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb. Cortex 18, 1575-1587. doi:10.1093/cercor/bhm186.
101. Murayama, M., Perez-Garci, E., Nevian, T., Bock, T., Senn, W., and Larkum, M. E. (2009). Dendritic encoding of sensory stimuli controlled by deep cortical interneurons. Nature 457, 1137-1141. doi:10.1038/nature07663.
102. Nanda, S. A., Qi, C., Roseboom, P. H., and Kalin, N. H. (2008). Predator stress induces behavioral inhibition and amygdala somatostatin receptor 2 gene expression. Genes Brain Behav. 7, 639-648. doi:10.1111/j.1601-183X.2008.00401.x.
103. Neggers, S. J., and van der Lely, A. J. (2009). Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat. Rev. Endocrinol. 5, 546-552. doi:10.1038/nrendo.2009.175.
104. Nilsson, A., Stroth, N., Zhang, X., Qi, H., Falth, M., Skold, K., et al. (2012). Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects. Neuropharmacology 62, 347-357. doi:10.1016/j.neuropharm.2011.08.004.
105. Nyegaard, M., Borglum, A. D., Bruun, T. G., Collier, D. A., Russ, C., Mors, O., et al. (2002). Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder. Mol. Psychiatry 7, 745-754. doi:10.1038/sj.mp.4001049.
106. Olias, G., Viollet, C., Kusserow, H., Epelbaum, J., and Meyerhof, W. (2004). Regulation and function of somatostatin receptors. J. Neurochem. 89, 1057-1091. doi:10.1111/j.1471-4159.2004.02402.x.
107. Padmos, R. C., Hillegers, M. H., Knijff, E. M., Vonk, R., Bouvy, A., Staal, F. J., et al. (2008). A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 65, 395-407. doi:10.1001/archpsyc.65.4.395.
108. Pallis, E., Vasilaki, A., Fehlmann, D., Kastellakis, A., Hoyer, D., Spyraki, C., et al. (2009). Antidepressants influence somatostatin levels and receptor pharmacology in brain. Neuropsychopharmacology 34, 952-963. doi:10.1038/npp.2008.133.
109. Pallis, E. G., Spyraki, C., and Thermos, K. (2006). Chronic antidepressant treatment modulates the release of somatostatin in the rat nucleus accumbens. Neurosci. Lett. 395, 76-81. doi:10.1016/j.neulet.2005.10.055.
110. Patel, Y. C. (1999). Somatostatin and its receptor family. Front. Neuroendocrinol. 20:157-198. doi:10.1006/frne.1999.0183.
111. Paus, T., Keshavan, M., and Giedd, J. N. (2008). Why do many psychiatric disorders emerge during adolescence? Nat. Rev. Neurosci. 9, 947-957. doi:10.1038/nrn2513.
112. Petrozzi, L., Ricci, G., Giglioli, N. J., Siciliano, G., and Mancuso, M. (2007). Mitochondria and neurodegeneration. Biosci. Rep. 27, 87-104. doi:10.1007/s10540-007-9038-z.
113. Pivonello, R., Ferone, D., Lamberts, S. W., and Colao, A. (2005). Cabergoline plus lanreotide for ectopic Cushing's syndrome. N. Engl. J. Med. 352, 2457-2458. doi:10.1056/NEJM200506093522322.
114. Ponomarev, I., Rau, V., Eger, E. I., Harris, R. A., and Fanselow, M. S. (2010). Amygdala transcriptome and cellular mechanisms underlying stress-enhanced fear learning in a rat model of posttraumatic stress disorder. Neuropsychopharmacology 35, 1402-1411. doi:10.1038/npp.2010.10.
115. Post, R. M., Rubinow, D. R., Kling, M. A., Berrettini, W., and Gold, P. W. (1988). Neuroactive substances in cerebrospinal fluid. Normal and pathological regulatory mechanisms. Ann. N. Y. Acad. Sci. 531, 15-28. doi:10.1111/j.1749-6632.1988.tb31808.x.
116. Prosperini, E., Rizzi, M., Fumagalli, F., Tarizzo, G., Samanin, R., and Bendotti, C. (1997). Acute and chronic treatments with citalopram lower somatostatin levels in rat brain striatum through different mechanisms. J. Neurochem. 69, 206-213. doi:10.1046/j.1471-4159.1997.69010206.x.
117. Rajkowska, G., O'Dwyer, G., Teleki, Z., Stockmeier, C. A., and Miguel-Hidalgo, J. J. (2007). GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 32, 471-482. doi:10.1038/sj.npp.1301234.
118. Reinikainen, K. J., Koponen, H., Jolkkonen, J., and Riekkinen, P. J. (1990). Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment. Psychiatry Res. 33, 307-312. doi:10.1016/0165-1781(90)90047-9.
119. Rivier, J., Erchegyi, J., Hoeger, C., Miller, C., Low, W., Wenger, S., et al. (2003). Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. J. Med. Chem. 46, 5579-5586. doi:10.1021/jm030243c.
120. Robas, N., Mead, E., and Fidock, M. (2003). MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J. Biol. Chem. 278, 44400-44404. doi:10.1074/jbc. M302456200.
121. Rocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., and Patel, Y. C. (2000). Receptors for dopamine and somatostatin:formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157. doi:10.1126/science.288.5463.154.
122. Rossor, M. N., Emson, P. C., Mountjoy, C. Q., Roth, M., and Iversen, L. L. (1980). Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci. Lett. 20, 373-377. doi:10.1016/0304-3940(80)90177-9.
123. Rubinow, D. R., Gold, P. W., Post, R. M., and Ballenger, J. C. (1985). CSF somatostatin in affective illness and normal volunteers. Prog. Neuropsychopharmacol. Biol. Psychiatry 9, 393-400. doi:10.1016/0278-5846(85)90192-7.
124. Rubinow, D. R., Gold, P. W., Post, R. M., Ballenger, J. C., Cowdry, R., Bollinger, J., et al. (1983). CSF somatostatin in affective illness. Arch. Gen. Psychiatry 40, 409-412. doi:10.1001/archpsyc.1983.01790040063009.
125. Rudy, B., Fishell, G., Lee, S., and Hjerling-Leffler, J. (2011). Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons. Dev. Neurobiol. 71, 45-61. doi:10.1002/dneu.20853.
126. Saveanu, A., Lavaque, E., Gunz, G., Barlier, A., Kim, S., Taylor, J. E., et al. (2002). Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 87, 5545-5552. doi:10.1210/jc.2002-020934.
127. Schmid, H. A., and Schoeffter, P. (2004). Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl. 1), 47-50. doi:10.1159/000080741.
128. Schreff, M., Schulz, S., Handel, M., Keilhoff, G., Braun, H., Pereira, G., et al. (2000). Distribution, targeting, and internalization of the sst4 somatostatin receptor in rat brain. J. Neurosci. 20, 3785-3797.
129. Schulz, S., Handel, M., Schreff, M., Schmidt, H., and Hollt, V. (2000). Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. J. Physiol. Paris 94, 259-264. doi:10.1016/S0928-4257(00)00212-6.
130. Sharif, N., Gendron, L., Wowchuk, J., Sarret, P., Mazella, J., Beaudet, A., et al. (2007). Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148, 2095-2105. doi:10.1210/en.2006-1266.
131. Sharma, R. P., Bissette, G., Janicak, P. G., Davis, J. M., and Nemeroff, C. B. (1995). Elevation of CSF somatostatin concentrations in mania. Am. J. Psychiatry 152, 1807-1809.
132. Sheppard, M., Shapiro, B., Pimstone, B., Kronheim, S., Berelowitz, M., and Gregory, M. (1979). Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J. Clin. Endocrinol. Metab. 48, 50-53. doi:10.1210/jcem-48-1-50.
133. Sibille, E., Morris, H. M., Kota, R. S., and Lewis, D. A. (2011). GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int. J. Neuropsychopharmacol. 14, 721-734. doi:10.1017/S1461145710001616.
134. Sicuteri, F., Geppetti, P., Marabini, S., and Lembeck, F. (1984). Pain relief by somatostatin in attacks of cluster headache. Pain 18, 359-365. doi:10.1016/0304-3959(84)90048-4.
135. Siehler, S., Nunn, C., Hannon, J., Feuerbach, D., and Hoyer, D. (2008). Pharmacological profile of somatostatin and cortistatin receptors. Mol. Cell. Endocrinol. 286, 26-34. doi:10.1016/j.mce.2007.12.007.
136. Sohal, R. S., and Weindruch, R. (1996). Oxidative stress, caloric restriction, and aging. Science 273, 59-63. doi:10.1126/science.273.5271.59.
137. Song, C., and Wang, H. (2011). Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 760-768. doi:10.1016/j.pnpbp.2010.06.020.
138. Sorce, S., and Krause, K. H. (2009). NOX enzymes in the central nervous system:from signaling to disease. Antioxid. Redox. Signal. 11, 2481-2504. doi:10.1089/ars.2009.2578.
139. Spier, A. D., and de Lecea, L. (2000). Cortistatin:a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Brain Res. Rev. 33, 228-241. doi:10.1016/S0165-0173(00)00031-X.
140. Stafford, R. S., Ausiello, J. C., Misra, B., and Saglam, D. (2000). National patterns of depression treatment in primary care. Prim. Care Companion J. Clin. Psychiatry 2, 211-216. doi:10.4088/PCC.v02n0603.
141. Stefanescu, C., and Ciobica, A. (2012). The relevance of oxidative stress status in first episode and recurrent depression. J. Affect. Disord. 143, 34-38. doi:10.1016/j.jad.2012.05.022.
142. Stroh, T., Kreienkamp, H. J., and Beaudet, A. (1999). Immunohistochemical distribution of the somatostatin receptor subtype 5 in the adult rat brain:predominant expression in the basal forebrain. J. Comp. Neurol. 412, 69-82. doi:10.1002/(SICI)1096-9861(19990913)412:1<69::AID-CNE5>3.0.CO;2-V.
143. Strowski, M. Z., Kohler, M., Chen, H. Y., Trumbauer, M. E., Li, Z., Szalkowski, D., et al. (2003). Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol. Endocrinol. 17, 93-106. doi:10.1210/me.2001-0035.
144. Szolcsanyi, J., Helyes, Z., Oroszi, G., Nemeth, J., and Pinter, E. (1998). Release of somatostatin and its role in the mediation of the anti-inflammatory effect induced by antidromic stimulation of sensory fibres of rat sciatic nerve. Br. J. Pharmacol. 123, 936-942. doi:10.1038/sj.bjp.0701685.
145. Tallent, M. K., and Qiu, C. (2008). Somatostatin:an endogenous antiepileptic. Mol. Cell. Endocrinol. 286, 96-103. doi:10.1016/j.mce.2007.12.004.
146. Tamminga, C. A., Foster, N. L., Fedio, P., Bird, E. D., and Chase, T. N. (1987). Alzheimer's disease:low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology 37, 161-165. doi:10.1212/WNL.37.1.161.
147. Tan, Z., Hu, H., Huang, Z. J., and Agmon, A. (2008). Robust but delayed thalamocortical activation of dendritic-targeting inhibitory interneurons. Proc. Natl. Acad. Sci. U.S.A. 105, 2187-2192. doi:10.1073/pnas.0710628105.
148. Taura, P., Planella, V., Balust, J., Beltran, J., Anglada, T., Carrero, E., et al. (1994). Epidural somatostatin as an analgesic in upper abdominal surgery:a double-blind study. Pain 59, 135-140. doi:10.1016/0304-3959(94)90057-4.
149. Tostivint, H., Lihrmann, I., and Vaudry, H. (2008). New insight into the molecular evolution of the somatostatin family. Mol. Cell. Endocrinol. 286, 5-17. doi:10.1016/j.mce.2008.02.029.
150. Tringali, G., Greco, M. C., Lisi, L., Pozzoli, G., and Navarra, P. (2012). Cortistatin modulates the expression and release of corticotrophin releasing hormone in rat brain. Comparison with somatostatin and octreotide. Peptides 34, 353-359. doi:10.1016/j.peptides.2012.02.004.
151. Tripp, A., Kota, R. S., Lewis, D. A., and Sibille, E. (2011). Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neurobiol. Dis. 42, 116-124. doi:10.1016/j.nbd.2011.01.014.
152. Tripp, A., Oh, H., Guilloux, J. P., Martinowich, K., Lewis, D. A., and Sibille, E. (2012). Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am. J. Psychiatry 169, 1194-1202. doi:10.1176/appi.ajp.2012.12020248.
153. Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:implications for clinical practice. Am. J. Psychiatry 163, 28-40. doi:10.1176/appi.ajp.163.1.28.
154. Vela, J., Gutierrez, A., Vitorica, J., and Ruano, D. (2003). Rat hippocampal GABAergic molecular markers are differentially affected by ageing. J. Neurochem. 85, 368-377. doi:10.1046/j.1471-4159.2003.01681.x.
155. Vepsalainen, S., Helisalmi, S., Koivisto, A. M., Tapaninen, T., Hiltunen, M., and Soininen, H. (2007). Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients. J. Neurol. 254, 1504-1508. doi:10.1007/s00415-007-0539-2.
156. Vezzani, A., and Hoyer, D. (1999). Brain somatostatin:a candidate inhibitory role in seizures and epileptogenesis. Eur. J. Neurosci. 11, 3767-3776. doi:10.1046/j.1460-9568.1999.00838.x.
157. Viollet, C., Lepousez, G., Loudes, C., Videau, C., Simon, A., and Epelbaum, J. (2008). Somatostatinergic systems in brain:networks and functions. Mol. Cell. Endocrinol. 286, 75-87. doi:10.1016/j.mce.2007.09.007.
158. Viollet, C., Vaillend, C., Videau, C., Bluet-Pajot, M. T., Ungerer, A., L'Héritier, A., et al. (2000). Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur. J. Neurosci. 12, 3761-3770. doi:10.1046/j.1460-9568.2000.00249.x.
159. Wang, A. Y., Lohmann, K. M., Yang, C. K., Zimmerman, E. I., Pantazopoulos, H., Herring, N., et al. (2011). Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region. Acta Neuropathol. 122, 615-626. doi:10.1007/s00401-011-0881-4.
160. Wang, X. M., Tresham, J. J., Coghlan, J. P., and Scoggins, B. A. (1987). Intracerebroventricular infusion of a cyclic hexapeptide analogue of somatostatin inhibits hemorrhage-induced ACTH release. Neuroendocrinology 45, 325-327. doi:10.1159/000124747.
161. Warren, T. G., and Shields, D. (1984). Expression of preprosomatostatin in heterologous cells:biosynthesis, posttranslational processing, and secretion of mature somatostatin. Cell 39, 547-555. doi:10.1016/0092-8674(84)90461-6.
162. Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., and Bruns, C. (2003). Opportunities in somatostatin research:biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. 2, 999-1017. doi:10.1038/nrd1255.
163. Wei, J., Xu, H., Davies, J. L., and Hemmings, G. P. (1992). Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci. 51, 1953-1956. doi:10.1016/0024-3205(92)90112-3.
164. Weiss, S. R., Nguyen, T., Rubinow, D. R., Helke, C. J., Narang, P. K., Post, R. M., et al. (1987). Lack of effect of chronic carbamazepine on brain somatostatin in the rat. J. Neural. Transm. 68, 325-333. doi:10.1007/BF02098507.
165. Wilson, N. R., Runyan, C. A., Wang, F. L., and Sur, M. (2012). Division and subtraction by distinct cortical inhibitory networks in vivo. Nature 488, 343-348. doi:10.1038/nature11347.
166. Xu, H., Jeong, H. Y., Tremblay, R., and Rudy, B. (2013). Neocortical somatostatin-expressing GABAergic interneurons disinhibit the thalamorecipient layer 4. Neuron 77, 155-167. doi:10.1016/j.neuron.2012.11.004.
167. Xu, X., Roby, K. D., and Callaway, E. M. (2010). Immunochemical characterization of inhibitory mouse cortical neurons:three chemically distinct classes of inhibitory cells. J. Comp. Neurol. 518, 389-404. doi:10.1002/cne.22229.
168. Xue, S., Jia, L., and Jia, J. (2009). Association between somatostatin gene polymorphisms and sporadic Alzheimer's disease in Chinese population. Neurosci. Lett. 465, 181-183. doi:10.1016/j.neulet.2009.09.002.
169. Yeung, M., Engin, E., and Treit, D. (2011). Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions. Psychopharmacology (Berl.) 216, 557-567. doi:10.1007/s00213-011-2248-x.
170. Zeyda, T., Diehl, N., Paylor, R., Brennan, M. B., and Hochgeschwender, U. (2001). Impairment in motor learning of somatostatin null mutant mice. Brain Res. 906, 107-114. doi:10.1016/S0006-8993(01)02563-X.
171. Zeyda, T., and Hochgeschwender, U. (2008). Null mutant mouse models of somatostatin and cortistatin, and their receptors. Mol. Cell. Endocrinol. 286, 18-25. doi:10.1016/j.mce.2007.11.029.